1xbet 모바일 Pharmaceutical Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Pharmaceuticals
June 7, 2019
1xbet 모바일 and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuticals' Drug Candidates in North America
1xbet 모바일 Pharmaceutical Co., Ltd. (1xbet 모바일) and Taiho Pharmaceutical Co., Ltd. announce that commercialization rights in the U.S. and Canada for anti-cancer drug candidates guadecitabine and ASTX727 will be transferred to Taiho Oncology, Inc. and Taiho Pharma Canada, Inc., respectively, from Astex Pharmaceuticals, an 1xbet 모바일 subsidiary. 1xbet 모바일 and Taiho are both part of the 1xbet 모바일 group of companies.
Taiho Pharmaceutical presently markets its ant1xbet 모바일eoplatic agent LONSURF® (trifluridine 1xbet 모바일 tipiracil) in the U.S. 1xbet 모바일 Canada, respectively, through subsidiaries Taiho Oncology 1xbet 모바일 Taiho Pharma Canada. Astex will remain responsible for development of its two promising, late-stage-development c1xbet 모바일idates, guadecitabine 1xbet 모바일 ASTX727.
1xbet 모바일 Pharmaceutical and Taiho Pharmaceutical aim to maximize their business impact and value by bringing together assets from across the 1xbet 모바일 group of companies, including their respective strengths and experiences in the oncologic, psychiatric, neurologic, cardiovascular and renal fields.
Astex's development-stage drug c1xbet 모바일idates for which North American commercialization rights will be transferred include:
| Guadecitab1xbet 모바일e |
Acute myeloid leukemia（AML） | Phase 3 | |
| Myelodysplastic syndrome（MDS） | Phase 3 | ||
| Ovarian cancer | Phase 2 | ||
| A next-generation, low-molecular-weight DNA methylation inhibitor that is designed to allow the active metabolite decitabine to work longer in the body 1xbet 모바일 thereby efficiently reach tissues such as the bone marrow. Therapeutic effects on patients with MDS 1xbet 모바일 AML are hypothesized to occur through restoration of the function of inactivated tumor suppressor genes in cancer cells, thereby suppressing cancer formation 1xbet 모바일 growth. | |||
|
ASTX727 |
Myelodysplastic syndrome（MDS） |
Phase 3 | |
|
The first-ever, fixed-dose-combination, oral DNA methylation inhibitor that combines the metabolic enzyme inhibitor cedazuridine with decitabine, the active ingredient of the DNA methylation inhibitor Dacogen. Preliminary results of phase 3 trials in patients with MDS indicated that the plasma drug concentration-time curve (AUC) 1xbet 모바일 pharmacodynamics, safety, 1xbet 모바일 tolerability were equivalent to those of Dacogen injections. |
|||
Latest Pharmaceutical Bus1xbet 모바일ess related News Releases